ESTALIS

Informació principal

  • Denominació comercial:
  • ESTALIS SEQUIDOT 50/250 mcg 4 + 4 parches transd
  • formulario farmacéutico:
  • Parche
  • Vía de administración:
  • Transdérmica
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • ESTALIS SEQUIDOT 50/250 mcg 4 + 4 parches transd
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 660867
  • última actualització:
  • 09-06-2018

Prospecte

ESTALIS SEQUIDOT 50/250 mcg 4 + 4 parches

transd

estradiol+noretisterona

Indicacions

Medicament utilitzat quan cal una aportaci

extra d'hormones sexuals femenines (ESTR

GENS I

PROGEST

GENS).

Consideracions

Conservi aquest medicament a la nevera (mai en el congelador).

s d'aquest medicament

s exclusiu per a dones.

Renti's les mans abans i despr

s de cada aplicaci

Netegi i assequi b

la zona a tractar abans de cada aplicaci

Apliqui's el pegat sobre la pell seca, no irradiada, no irritada, sense ferides i sense borrissol (pot tallar el

borrissol amb tisores, per

no afaitar-lo).

Ha de canviar el pegat cada 3 dies, variant el lloc d'aplicaci

Si ha d'aplicar un nou pegat, canvi

el lloc d'aplicaci

, per a qu

la pell no s'irriti.

No talli ni utilitzi pegats perforats o deteriorats.

Ha de guardar els pegats en un lloc sec, i evitar la calor i la llum solar directa.

Pot banyar-se, dutxar-se o practicar nataci

amb el pegat, per

eviti exposar-ho a una calor excessiva.

Si el pegat cau, intenti tornar a col

locar-ho. Si no

s possible, tiri-ho i apliqui un de nou.

Avisi el seu metge si pateix intoler

ncia a alguns sucres, diabetis o hipertensi

Avisi el seu metge si pateix o ha patit problemes de circulaci

, problemes de fetge, problemes de

tiroides o problemes de rony

Aquest medicament modifica l'acci

d'altres f

rmacs, NO prengui altres medicaments sense consultar

abans al seu metge o farmac

utic.

Informi immediatament el seu metge si est

embarassada o creu que pot estar-ho, aix

com si qued

s embarassada durant el tractament.

Avisi al seu metge si t

algun fill a qui estigui alletant.

Efectes adversos

Aquest medicament pot produir envermelliment o mol

sties al punt d'aplicaci

, dolor als pits, sagnats

irregulars i mal de cap.

Si not

s qualsevol altre s

mptoma que creu que pot ser causat per aquest medicament, digui-li-ho al

seu metge.

Posologia

Aplicar 1 pegat sobre la pell neta.

S'ha de canviar el pegat cada 3-4 dies, rotant el lloc d'aplicaci

VIA TRANSD

RMICA.

3-11-2018

Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM 1/35 and two lots of ORTHO-NOVUM 7/7/7 Due to Incorrect Veridate Dispenser Instructions

Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM 1/35 and two lots of ORTHO-NOVUM 7/7/7 Due to Incorrect Veridate Dispenser Instructions

Janssen Pharmaceuticals, Inc. has initiated a voluntary recall of one lot of ORTHO-NOVUM 1/35 (norethindrone / ethinyl estradiol) Tablets and two lots of ORTHO-NOVUM 7/7/7 (norethindrone / ethinyl estradiol) Tablets to the pharmacy level. The patient information provided inside affected packages of ORTHO-NOVUM does not include the appropriate instructions for the Veridate dispenser.

FDA - U.S. Food and Drug Administration

10-8-2018

FDA approves new vaginal ring for one year of birth control

FDA approves new vaginal ring for one year of birth control

FDA approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration